2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1555

E-Comorbidity: Evaluation of the Validity of Electronic Comorbidity Assessment in Identifying Comorbid Conditions Among Patients with Rheumatoid and Psoriatic Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1623

Early Effects of Tofacitinib on Bone Homeostasis in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1457

Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1703

Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1619

EARTH EXPLORER 2, a Phase IIb Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and the Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1273

Effect of Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Early Rheumatoid Arthritis Patients Using HR-pQCT: A Cross-Sectional Study

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1640

Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1687

Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1764

Effect of Disease Remission on Organ Damage and Quality of Life in Chinese Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1742

Effect of DMARD Therapies on NSAID Intake, Quality of Life, and Physical Functioning in Patients with Ankylosing Spondylitis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1382

Effect of Lupus Anticoagulant on Rotational Thromboelastometry in Juvenile Systemic Lupus Erythematosus: Preliminary Data on a Single Center Cohort

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1434

Effect of Systemic and Local Inflammation on the Insulin Resistance and Glucose/Lipid Metabolism in Rheumatoid Arthritis: Humans and CIA Mouse Model

Rheumatoid Arthritis – Animal Models - Poster II

9:00AM-11:00AM: Abstract Number: 1337

Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1158

Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with Rheumatoid Arthritis

Education - ARHP Poster

9:00AM-11:00AM: Abstract Number: 1748

Effects of Anti-High Mobility Group Box 1 Antibody for MRL/Lpr lupus-Prone Mice

Systemic Lupus Erythematosus – Animal Models - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].